A single nanoparticle delivers two therapies at once - and eliminated colon tumors in mice within 30 days

A lipid nanoparticle that simultaneously blocks an immune-suppressing enzyme and instructs cells to produce a powerful immune activator eliminated established colon tumors in mice within 30 days, prevented recurrence, and triggered anti-tumor immunity throughout the body - including in tumors that were never directly treated.

The results, published March 18 in Nature Nanotechnology, come from a team at the University of Pennsylvania led by Michael J. Mitchell, associate professor of bioengineering. The approach targets a central problem in cancer immunotherapy: the exhaustion of T cells inside solid tumors.

T cells running on empty

The immune system's primary weapon against cancer is the CD8+ T cell - a specialized killer cell that can identify and destroy abnormal cells. In principle, T cells should eliminate cancer. In practice, solid tumors fight back.

Tumors create a hostile microenvironment that systematically disables immune cells. They deprive T cells of nutrients, flood them with suppressive signals, and produce enzymes that dampen immune activity. One of the most important of these enzymes is indoleamine 2,3-dioxygenase (IDO), which depletes an amino acid called tryptophan that T cells need to function. Over time, T cells exposed to this environment lose their ability to proliferate, produce signaling molecules, and kill cancer cells - a state known as T-cell exhaustion.

Qiangqiang Shi, a postdoctoral fellow in Mitchell's lab and co-first author of the study, offered a vivid analogy: inside a solid tumor, T cells are like cars trying to drive with one foot on the brake and almost no fuel in the tank. The new nanoparticle releases the brake and refuels the T cells at the same time.

This dual problem - active suppression plus metabolic starvation - is why treatments like CAR-T cell therapy, which have transformed outcomes for certain blood cancers, have largely failed against solid tumors. Engineered T cells can be designed to recognize cancer, but once they enter the tumor microenvironment, they often become exhausted before they can do their work.

Building the drug into the delivery vehicle

Lipid nanoparticles (LNPs) are best known as the delivery vehicles used in mRNA COVID-19 vaccines. They consist of a shell of lipid molecules enclosing a cargo - typically mRNA that instructs cells to produce a specific protein. The Penn team took this concept in a new direction.

Rather than simply packaging two separate therapies together, the researchers chemically conjugated an IDO-inhibiting drug directly to one of the nanoparticle's structural components: the ionizable lipid. This lipid is the component that helps the particle enter cells and release its contents. By making the drug part of the lipid itself, the team created what they call a prodrug lipid nanoparticle (pLNP) - a single structure that is simultaneously delivery vehicle and therapy.

Inside the tumor, the drug-lipid bond breaks down, releasing the IDO inhibitor locally. Meanwhile, the mRNA cargo carried within the particle instructs the tumor's own cells to produce interleukin-12 (IL-12), a potent immune-stimulating protein that activates T cells and natural killer cells.

Jinjin Wang, a postdoctoral fellow on the team, emphasized the design philosophy. The lipid does not just help deliver a therapy. It becomes part of the therapy. This is the first time an IDO inhibitor has been conjugated to the ionizable lipid component specifically, though other groups have attached similar drugs to other LNP components like cholesterol.

Seven controls, one clear winner

The team tested the pLNP against seven different control groups to establish that the dual-action design was genuinely necessary. Delivering the IDO inhibitor alone provided only partial tumor control. Delivering IL-12 mRNA alone also showed limited effect. Even delivering both therapies simultaneously but in separate particles did not match the performance of the combined pLNP.

Hannah Geisler, a doctoral student involved in the study, emphasized that putting both components into one particle produced a much stronger immune response than delivering them separately. The synergy required co-delivery in a single vehicle.

In mice with established colon tumors, intratumoral injection of pLNPs nearly eliminated tumors within 30 days. Treated tumors showed higher numbers of killer T cells, fewer immune-suppressive regulatory T cells, and lower levels of PD-1 - a molecular marker of T-cell exhaustion. Tumors that had been immunologically "cold" - invisible to the immune system - were transformed into "hot," inflamed tumors rich in active immune cells.

Immunity that traveled beyond the injection site

Perhaps the most striking finding involved mice bearing tumors on both sides of their bodies. When researchers injected pLNPs into just one tumor, the untreated tumor on the opposite side also regressed. This abscopal effect - immune activity at a distant site triggered by local treatment - suggests the nanoparticle was not merely acting on the treated tumor but retraining the immune system to recognize and attack cancer cells wherever they appeared.

Mice that had completely cleared their tumors also resisted subsequent attempts to regrow the same cancer, indicating the immune system had developed lasting memory against the tumor cells. This happened despite the therapy never directly targeting any tumor-specific molecular marker. The immune system found and remembered the targets on its own.

The toxicity trade-off with systemic delivery

Direct injection into tumors produced strong anti-cancer effects with minimal toxicity. Intravenous delivery told a different story. While IV administration produced moderate tumor suppression, it also elevated circulating inflammatory cytokines and liver stress markers - side effects that have historically plagued IL-12 therapy and limited its clinical development.

This is not a minor caveat. Direct intratumoral injection works well for accessible tumors - a superficial mass that can be reached with a needle under imaging guidance. But many solid tumors are deep within organs, surrounded by critical structures, or distributed across multiple sites. Reaching them requires systemic delivery, and the toxicity observed with IV administration represents a significant hurdle.

The team is actively working on solutions. One approach involves attaching tumor-targeting antibodies to the nanoparticle surface to improve delivery specificity and reduce liver accumulation. Another involves engineering new chemical linkers that respond to specific features of the tumor microenvironment - acidity, enzymes, or oxidative stress - to ensure the drug is released only at the intended site.

Preclinical results, clinical distance

The pLNP has not been tested in humans, and the gap between eliminating tumors in mice and treating cancer in patients is famously wide. Mouse immune systems differ from human immune systems in important ways, and tumor models in mice - often involving a single cell line injected under the skin - do not capture the heterogeneity, immune evasion mechanisms, and genetic complexity of human cancers.

The platform's adaptability is one of its strengths. The researchers are exploring additional immune-stimulating mRNAs beyond IL-12 to broaden the range of immune signals the particle can deliver. The modular design means that different drug-lipid conjugates and different mRNA cargoes can be tested in various combinations, potentially tailoring the approach to different cancer types.

Mitchell frames the next steps pragmatically. The platform has shown it can restore immune function inside solid tumors. Refining and expanding it for safe, effective clinical translation is the work ahead.